Afficher la notice abrégée

dc.contributor.authorMartín Contreras, Marina
dc.contributor.authorNavarro Marchal, Saul Abenhamar 
dc.contributor.authorPeula García, José Manuel
dc.contributor.authorJódar Reyes, Ana Belén 
dc.date.accessioned2022-03-28T10:54:35Z
dc.date.available2022-03-28T10:54:35Z
dc.date.issued2022-02-10
dc.identifier.citationMartín-Contreras, M... [et al.]. Progress and Hurdles of Therapeutic Nanosystems against Cancer. Pharmaceutics 2022, 14, 388. [https://doi.org/10.3390/pharmaceutics14020388]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/73837
dc.descriptionThis research was funded by FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades, Projects (PY20_00241 and A-FQM-90-UGR20).es_ES
dc.description.abstractNanomedicine against cancer, including diagnosis, prevention and treatment, has increased expectations for the solution of many biomedical challenges in the fight against this disease. In recent decades, an exhaustive design of nanosystems with high specificity, sensitivity and selectivity has been achieved due to a rigorous control over their physicochemical properties and an understanding of the nano–bio interface. However, despite the considerable progress that has been reached in this field, there are still different hurdles that limit the clinical application of these nanosystems, which, along with their possible solutions, have been reviewed in this work. Specifically, physiological processes as biological barriers and protein corona formation related to the administration routes, designing strategies to overcome these obstacles, promising new multifunctional nanotherapeutics, and recent clinical trials are presented in this review.es_ES
dc.description.sponsorshipFEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades PY20_00241 A-FQM-90-UGR20es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectNanomedicinees_ES
dc.subjectDesign of nanosystemses_ES
dc.subjectPhysicochemical propertieses_ES
dc.subjectProtein coronaes_ES
dc.subjectTargetinges_ES
dc.subjectDeliveryes_ES
dc.subjectClinical applicationes_ES
dc.titleProgress and Hurdles of Therapeutic Nanosystems against Canceres_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/pharmaceutics14020388
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 3.0 España
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 3.0 España